GLP-1 receptor agonists — including semaglutide, sold as Ozempic and Rybelsus for diabetes and as Wegovy for weight loss — are among the most prescribed drugs in America. Starting in 2024, researchers linked them to NAION, a stroke-like injury to the optic nerve that causes sudden, usually permanent vision loss in one eye. In December 2025, the Judicial Panel on Multidistrict Litigation created a dedicated federal MDL (No. 3163) in the Eastern District of Pennsylvania to consolidate these vision-loss claims, keeping them separate from an earlier GLP-1 gastrointestinal-injury litigation. The court held a Science Day in June 2026 and cases continue to be filed. If you lost vision after taking a GLP-1 drug, you may qualify to have your claim reviewed.
From the docket
Litigation Timeline
- June 2, 2026
MDL holds Science Day as cases mountregulatory
The court holds a Science Day to educate the judge on the medical evidence behind the NAION claims. Roughly 110 cases are pending in the MDL as of June 2026, with more being filed.
- December 2025
JPML creates the GLP-1 vision-loss MDL — No. 3163filing
The U.S. Judicial Panel on Multidistrict Litigation creates In re GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163, in the Eastern District of Pennsylvania before Judge Karen Marston, keeping the vision-loss claims separate from an earlier GLP-1 gastrointestinal-injury litigation.
- July 2024
Harvard study in JAMA Ophthalmology links semaglutide to NAIONscientific
A Harvard Medical School team publishes a study in JAMA Ophthalmology reporting that patients prescribed semaglutide had a substantially higher risk of NAION — a hazard ratio of 4.28 among people with type 2 diabetes and 7.64 among overweight or obese patients. The authors note the study is observational and call for further research.
Stay informed
Get free updates on the GLP-1 Vision Loss (Ozempic / Wegovy NAION) litigation as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Full case details
Want the complete picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View the full GLP-1 Vision Loss (Ozempic / Wegovy NAION) case page →